Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 234

1.

PTEN isoforms with dual and opposing function.

Taylor J, Abdel-Wahab O.

Nat Cell Biol. 2019 Nov;21(11):1306-1308. doi: 10.1038/s41556-019-0405-3. No abstract available.

PMID:
31685989
2.

Altered RNA Processing in Cancer Pathogenesis and Therapy.

Obeng EA, Stewart C, Abdel-Wahab O.

Cancer Discov. 2019 Nov;9(11):1493-1510. doi: 10.1158/2159-8290.CD-19-0399. Epub 2019 Oct 14. Review.

PMID:
31611195
3.

Spliceosomal disruption of the non-canonical BAF complex in cancer.

Inoue D, Chew GL, Liu B, Michel BC, Pangallo J, D'Avino AR, Hitchman T, North K, Lee SC, Bitner L, Block A, Moore AR, Yoshimi A, Escobar-Hoyos L, Cho H, Penson A, Lu SX, Taylor J, Chen Y, Kadoch C, Abdel-Wahab O, Bradley RK.

Nature. 2019 Oct;574(7778):432-436. doi: 10.1038/s41586-019-1646-9. Epub 2019 Oct 9.

PMID:
31597964
4.

Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis.

Yoshimi A, Lin KT, Wiseman DH, Rahman MA, Pastore A, Wang B, Lee SC, Micol JB, Zhang XJ, de Botton S, Penard-Lacronique V, Stein EM, Cho H, Miles RE, Inoue D, Albrecht TR, Somervaille TCP, Batta K, Amaral F, Simeoni F, Wilks DP, Cargo C, Intlekofer AM, Levine RL, Dvinge H, Bradley RK, Wagner EJ, Krainer AR, Abdel-Wahab O.

Nature. 2019 Oct;574(7777):273-277. doi: 10.1038/s41586-019-1618-0. Epub 2019 Oct 2.

PMID:
31578525
5.

Muscarinic acetylcholine receptor regulates self-renewal of early erythroid progenitors.

Trivedi G, Inoue D, Chen C, Bitner L, Chung YR, Taylor J, Gönen M, Wess J, Abdel-Wahab O, Zhang L.

Sci Transl Med. 2019 Sep 25;11(511). pii: eaaw3781. doi: 10.1126/scitranslmed.aaw3781.

PMID:
31554738
6.

Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.

Fong JY, Pignata L, Goy PA, Kawabata KC, Lee SC, Koh CM, Musiani D, Massignani E, Kotini AG, Penson A, Wun CM, Shen Y, Schwarz M, Low DH, Rialdi A, Ki M, Wollmann H, Mzoughi S, Gay F, Thompson C, Hart T, Barbash O, Luciani GM, Szewczyk MM, Wouters BJ, Delwel R, Papapetrou EP, Barsyte-Lovejoy D, Arrowsmith CH, Minden MD, Jin J, Melnick A, Bonaldi T, Abdel-Wahab O, Guccione E.

Cancer Cell. 2019 Aug 12;36(2):194-209.e9. doi: 10.1016/j.ccell.2019.07.003.

PMID:
31408619
7.

Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis.

Taylor J, Sendino M, Gorelick AN, Pastore A, Chang MT, Penson AV, Gavrila EI, Stewart C, Melnik EM, Herrejon Chavez F, Bitner L, Yoshimi A, Lee SC, Inoue D, Liu B, Zhang XJ, Mato AR, Dogan A, Kharas MG, Chen Y, Wang D, Soni RK, Hendrickson RC, Prieto G, Rodriguez JA, Taylor BS, Abdel-Wahab O.

Cancer Discov. 2019 Oct;9(10):1452-1467. doi: 10.1158/2159-8290.CD-19-0298. Epub 2019 Jul 8.

PMID:
31285298
8.

Somatic mutations and cell identity linked by Genotyping of Transcriptomes.

Nam AS, Kim KT, Chaligne R, Izzo F, Ang C, Taylor J, Myers RM, Abu-Zeinah G, Brand R, Omans ND, Alonso A, Sheridan C, Mariani M, Dai X, Harrington E, Pastore A, Cubillos-Ruiz JR, Tam W, Hoffman R, Rabadan R, Scandura JM, Abdel-Wahab O, Smibert P, Landau DA.

Nature. 2019 Jul;571(7765):355-360. doi: 10.1038/s41586-019-1367-0. Epub 2019 Jul 3.

PMID:
31270458
9.

Erdheim-Chester Disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1.

Razanamahery J, Diamond EL, Cohen-Aubart F, Plate KH, Lourida G, Charlotte F, Hélias-Rodzewicz Z, Goyal G, Go RS, Dogan A, Abdel-Wahab O, Durham B, Ozkaya N, Amoura Z, Emile JF, Haroche J.

Haematologica. 2019 May 23. pii: haematol.2019.216937. doi: 10.3324/haematol.2019.216937. [Epub ahead of print]

10.

Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.

Duy C, Teater M, Garrett-Bakelman FE, Lee TC, Meydan C, Glass JL, Li M, Hellmuth JC, Mohammad HP, Smitheman KN, Shih AH, Abdel-Wahab O, Tallman MS, Guzman ML, Muench D, Grimes HL, Roboz GJ, Kruger RG, Creasy CL, Paietta EM, Levine RL, Carroll M, Melnick AM.

Cancer Discov. 2019 Jul;9(7):872-889. doi: 10.1158/2159-8290.CD-19-0106. Epub 2019 May 10.

PMID:
31076479
11.

Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL.

Pastore A, Gaiti F, Lu SX, Brand RM, Kulm S, Chaligne R, Gu H, Huang KY, Stamenova EK, Béguelin W, Jiang Y, Schulman RC, Kim KT, Alonso A, Allan JN, Furman RR, Gnirke A, Wu CJ, Melnick AM, Meissner A, Bernstein BE, Abdel-Wahab O, Landau DA.

Nat Commun. 2019 Apr 23;10(1):1874. doi: 10.1038/s41467-019-09645-5.

12.

Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.

Janku F, Diamond EL, Goodman AM, Raghavan VK, Barnes TG, Kato S, Abdel-Wahab O, Durham BH, Meric-Bernstam F, Kurzrock R.

Mol Cancer Ther. 2019 Jun;18(6):1149-1157. doi: 10.1158/1535-7163.MCT-18-1244. Epub 2019 Apr 23.

13.

A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease.

Diamond EL, Reiner AS, Buthorn JJ, Shuk E, Applebaum AJ, Hyman DM, Abdel-Wahab O, Rampal R, Janku F, Brewer K, Campbell J, Mao JJ, Atkinson TM, Panageas KS.

Blood Adv. 2019 Apr 9;3(7):934-938. doi: 10.1182/bloodadvances.2018030502.

14.

Efficacy of MEK inhibition in patients with histiocytic neoplasms.

Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM.

Nature. 2019 Mar;567(7749):521-524. doi: 10.1038/s41586-019-1012-y. Epub 2019 Mar 13.

15.

Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia.

Wang E, Lu SX, Pastore A, Chen X, Imig J, Chun-Wei Lee S, Hockemeyer K, Ghebrechristos YE, Yoshimi A, Inoue D, Ki M, Cho H, Bitner L, Kloetgen A, Lin KT, Uehara T, Owa T, Tibes R, Krainer AR, Abdel-Wahab O, Aifantis I.

Cancer Cell. 2019 Mar 18;35(3):369-384.e7. doi: 10.1016/j.ccell.2019.01.010. Epub 2019 Feb 21.

PMID:
30799057
16.

BRAF in the cross-hairs.

Geyer MB, Abdel-Wahab O, Tallman MS.

Expert Rev Hematol. 2019 Mar;12(3):183-193. doi: 10.1080/17474086.2019.1583553. Epub 2019 Feb 26.

PMID:
30782032
17.

Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900.

Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta E, Racevskis J, Levine RL, Patel JP, Abdel-Wahab O, Ketterling RP, Dewald GW, Bennett JM, Rowe JM, Lazarus HM, Tallman MS.

Haematologica. 2019 Apr;104(4):e147-e150. doi: 10.3324/haematol.2018.197277. Epub 2018 Nov 22. No abstract available.

18.

Activating p53 and Inhibiting Superenhancers to Cure Leukemia.

Ball B, Abdel-Wahab O.

Trends Pharmacol Sci. 2018 Dec;39(12):1002-1004. doi: 10.1016/j.tips.2018.10.009.

PMID:
30454768
19.

A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia.

Spiciarich DR, Oh ST, Foley A, Hughes SB, Mauro MJ, Abdel-Wahab O, Press RD, Viner R, Thompson SL, Chen Q, Azadi P, Bertozzi CR, Maxson JE.

Cancer Res. 2018 Dec 15;78(24):6762-6770. doi: 10.1158/0008-5472.CAN-18-1638. Epub 2018 Oct 22.

PMID:
30348809
20.

Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene U2af1.

Fei DL, Zhen T, Durham B, Ferrarone J, Zhang T, Garrett L, Yoshimi A, Abdel-Wahab O, Bradley RK, Liu P, Varmus H.

Proc Natl Acad Sci U S A. 2018 Oct 30;115(44):E10437-E10446. doi: 10.1073/pnas.1812669115. Epub 2018 Oct 15.

21.

ProteomeGenerator: A Framework for Comprehensive Proteomics Based on de Novo Transcriptome Assembly and High-Accuracy Peptide Mass Spectral Matching.

Cifani P, Dhabaria A, Chen Z, Yoshimi A, Kawaler E, Abdel-Wahab O, Poirier JT, Kentsis A.

J Proteome Res. 2018 Nov 2;17(11):3681-3692. doi: 10.1021/acs.jproteome.8b00295. Epub 2018 Oct 19.

22.

Widespread intronic polyadenylation inactivates tumour suppressor genes in leukaemia.

Lee SH, Singh I, Tisdale S, Abdel-Wahab O, Leslie CS, Mayr C.

Nature. 2018 Sep;561(7721):127-131. doi: 10.1038/s41586-018-0465-8. Epub 2018 Aug 27.

23.

Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations.

Lee SC, North K, Kim E, Jang E, Obeng E, Lu SX, Liu B, Inoue D, Yoshimi A, Ki M, Yeo M, Zhang XJ, Kim MK, Cho H, Chung YR, Taylor J, Durham BH, Kim YJ, Pastore A, Monette S, Palacino J, Seiler M, Buonamici S, Smith PG, Ebert BL, Bradley RK, Abdel-Wahab O.

Cancer Cell. 2018 Aug 13;34(2):225-241.e8. doi: 10.1016/j.ccell.2018.07.003.

24.

Cancer-Specific Splicing Changes and the Potential for Splicing-Derived Neoantigens.

Hoyos LE, Abdel-Wahab O.

Cancer Cell. 2018 Aug 13;34(2):181-183. doi: 10.1016/j.ccell.2018.07.008.

25.

Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms.

Mughal TI, Lion T, Abdel-Wahab O, Mesa R, Scherber RM, Perrotti D, Mauro M, Verstovsek S, Saglio G, Van Etten RA, Kralovics R.

Hematol Oncol. 2018 Dec;36(5):740-748. doi: 10.1002/hon.2537. Epub 2018 Aug 3. Review.

26.

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.

Leeksma AC, Taylor J, Wu B, Gardner JR, He J, Nahas M, Gonen M, Alemayehu WG, Te Raa D, Walther T, Hüllein J, Dietrich S, Claus R, de Boer F, de Heer K, Dubois J, Dampmann M, Dürig J, van Oers MHJ, Geisler CH, Eldering E, Levine RL, Miller V, Mughal T, Lamanna N, Frattini MG, Heaney ML, Zelenetz A, Zenz T, Abdel-Wahab O, Kater AP.

Leukemia. 2019 Feb;33(2):390-402. doi: 10.1038/s41375-018-0215-9. Epub 2018 Jul 23.

27.

Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.

Taylor J, Pavlick D, Yoshimi A, Marcelus C, Chung SS, Hechtman JF, Benayed R, Cocco E, Durham BH, Bitner L, Inoue D, Chung YR, Mullaney K, Watts JM, Diamond EL, Albacker LA, Mughal TI, Ebata K, Tuch BB, Ku N, Scaltriti M, Roshal M, Arcila M, Ali S, Hyman DM, Park JH, Abdel-Wahab O.

J Clin Invest. 2018 Aug 31;128(9):3819-3825. doi: 10.1172/JCI120787. Epub 2018 Aug 6.

28.

KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function.

Gala K, Li Q, Sinha A, Razavi P, Dorso M, Sanchez-Vega F, Chung YR, Hendrickson R, Hsieh JJ, Berger M, Schultz N, Pastore A, Abdel-Wahab O, Chandarlapaty S.

Oncogene. 2018 Aug;37(34):4692-4710. doi: 10.1038/s41388-018-0273-5. Epub 2018 May 14.

29.

Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs.

Chang CJ, Kotini AG, Olszewska M, Georgomanoli M, Teruya-Feldstein J, Sperber H, Sanchez R, DeVita R, Martins TJ, Abdel-Wahab O, Bradley RK, Papapetrou EP.

Stem Cell Reports. 2018 May 8;10(5):1610-1624. doi: 10.1016/j.stemcr.2018.03.020. Epub 2018 Apr 19.

30.

Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation.

Nagase R, Inoue D, Pastore A, Fujino T, Hou HA, Yamasaki N, Goyama S, Saika M, Kanai A, Sera Y, Horikawa S, Ota Y, Asada S, Hayashi Y, Kawabata KC, Takeda R, Tien HF, Honda H, Abdel-Wahab O, Kitamura T.

J Exp Med. 2018 Jun 4;215(6):1729-1747. doi: 10.1084/jem.20171151. Epub 2018 Apr 11.

31.

Editorial overview: Cancer genomics: RNA metabolism and translation in cancer pathogenesis and therapy.

Abdel-Wahab O, Gebauer F.

Curr Opin Genet Dev. 2018 Feb;48:iv-vi. doi: 10.1016/j.gde.2018.01.007. No abstract available.

32.

SETD2 - linking stem cell survival and transformation.

Patnaik MM, Abdel-Wahab O.

Cell Res. 2018 Apr;28(4):393-394. doi: 10.1038/s41422-018-0025-7. No abstract available.

33.

The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.

Lin R, Xia S, Shan C, Chen D, Liu Y, Gao X, Wang M, Kang HB, Pan Y, Liu S, Chung YR, Abdel-Wahab O, Merghoub T, Rossi M, Kudchadkar RR, Lawson DH, Khuri FR, Lonial S, Chen J.

Mol Cell. 2018 Mar 15;69(6):923-937.e8. doi: 10.1016/j.molcel.2018.02.010.

34.

Targeting mRNA Decapping in AML.

Yoshimi A, Abdel-Wahab O.

Cancer Cell. 2018 Mar 12;33(3):339-341. doi: 10.1016/j.ccell.2018.02.015.

35.

Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties.

Gao Y, Chang MT, McKay D, Na N, Zhou B, Yaeger R, Torres NM, Muniz K, Drosten M, Barbacid M, Caponigro G, Stuart D, Moebitz H, Solit DB, Abdel-Wahab O, Taylor BS, Yao Z, Rosen N.

Cancer Discov. 2018 May;8(5):648-661. doi: 10.1158/2159-8290.CD-17-1452. Epub 2018 Feb 26.

36.

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

Bhatia A, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Lacouture ME, Hajdenberg J, Ganzel C, Diamond EL.

Haematologica. 2018 Apr;103(4):e177-e180. doi: 10.3324/haematol.2017.185298. Epub 2018 Feb 22. No abstract available.

37.

Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.

Mughal TI, Gotlib J, Mesa R, Koschmieder S, Khoury HJ, Cortes JE, Barbui T, Hehlmann R, Mauro M, Saussele S, Radich JP, Van Etten RA, Saglio G, Verstovek S, Gale RP, Abdel-Wahab O.

Leuk Res. 2018 Apr;67:67-74. doi: 10.1016/j.leukres.2018.02.008. Epub 2018 Feb 14. Review.

38.

H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.

Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, Agrawal AA, Caleb B, Csibi A, Sean E, Fekkes P, Karr C, Klimek V, Lai G, Lee L, Kumar P, Lee SC, Liu X, Mackenzie C, Meeske C, Mizui Y, Padron E, Park E, Pazolli E, Peng S, Prajapati S, Taylor J, Teng T, Wang J, Warmuth M, Yao H, Yu L, Zhu P, Abdel-Wahab O, Smith PG, Buonamici S.

Nat Med. 2018 May;24(4):497-504. doi: 10.1038/nm.4493. Epub 2018 Feb 19.

39.

The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations.

Chen L, Chen JY, Huang YJ, Gu Y, Qiu J, Qian H, Shao C, Zhang X, Hu J, Li H, He S, Zhou Y, Abdel-Wahab O, Zhang DE, Fu XD.

Mol Cell. 2018 Feb 1;69(3):412-425.e6. doi: 10.1016/j.molcel.2017.12.029. Epub 2018 Jan 27.

40.

The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort.

Ozkaya N, Rosenblum MK, Durham BH, Pichardo JD, Abdel-Wahab O, Hameed MR, Busam KJ, Travis WD, Diamond EL, Dogan A.

Mod Pathol. 2018 Apr;31(4):581-597. doi: 10.1038/modpathol.2017.160. Epub 2017 Dec 1. Review.

41.

Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.

Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, Lacouture M, Elez E, Martínez-Valle F, Durham B, Arcila ME, Ulaner G, Abdel-Wahab O, Pitcher B, Makrutzki M, Riehl T, Baselga J, Hyman DM.

JAMA Oncol. 2018 Mar 1;4(3):384-388. doi: 10.1001/jamaoncol.2017.5029. Erratum in: JAMA Oncol. 2019 Jan 1;5(1):122.

42.

Therapeutic targeting of RNA splicing in myelodysplasia.

Kim YJ, Abdel-Wahab O.

Semin Hematol. 2017 Jul;54(3):167-173. doi: 10.1053/j.seminhematol.2017.06.007. Epub 2017 Jul 12. Review.

PMID:
28958291
43.

A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease.

Mass E, Jacome-Galarza CE, Blank T, Lazarov T, Durham BH, Ozkaya N, Pastore A, Schwabenland M, Chung YR, Rosenblum MK, Prinz M, Abdel-Wahab O, Geissmann F.

Nature. 2017 Sep 21;549(7672):389-393. doi: 10.1038/nature23672. Epub 2017 Aug 30.

44.

Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.

Cimmino L, Dolgalev I, Wang Y, Yoshimi A, Martin GH, Wang J, Ng V, Xia B, Witkowski MT, Mitchell-Flack M, Grillo I, Bakogianni S, Ndiaye-Lobry D, Martín MT, Guillamot M, Banh RS, Xu M, Figueroa ME, Dickins RA, Abdel-Wahab O, Park CY, Tsirigos A, Neel BG, Aifantis I.

Cell. 2017 Sep 7;170(6):1079-1095.e20. doi: 10.1016/j.cell.2017.07.032. Epub 2017 Aug 17.

45.

Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations.

Durham BH, Getta B, Dietrich S, Taylor J, Won H, Bogenberger JM, Scott S, Kim E, Chung YR, Chung SS, Hüllein J, Walther T, Wang L, Lu SX, Oakes CC, Tibes R, Haferlach T, Taylor BS, Tallman MS, Berger MF, Park JH, Zenz T, Abdel-Wahab O.

Blood. 2017 Oct 5;130(14):1644-1648. doi: 10.1182/blood-2017-01-765107. Epub 2017 Aug 11.

46.

Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.

Zarnegar S, Durham BH, Khattar P, Shukla NN, Benayed R, Lacouture ME, Lavi E, Lyden DC, Diamond EL, Dunkel IJ, Abdel-Wahab O.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26699. Epub 2017 Jul 27.

47.

High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis.

Papo M, Diamond EL, Cohen-Aubart F, Emile JF, Roos-Weil D, Gupta N, Durham BH, Ozkaya N, Dogan A, Ulaner GA, Rampal R, Kahn JE, Sené T, Charlotte F, Hervier B, Besnard C, Bernard OA, Settegrana C, Droin N, Hélias-Rodzewicz Z, Amoura Z, Abdel-Wahab O, Haroche J.

Blood. 2017 Aug 24;130(8):1007-1013. doi: 10.1182/blood-2017-01-761718. Epub 2017 Jul 5.

48.

Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms.

Ozkaya N, Dogan A, Abdel-Wahab O.

Hematol Oncol Clin North Am. 2017 Aug;31(4):705-719. doi: 10.1016/j.hoc.2017.04.008. Epub 2017 May 17. Review. Erratum in: Hematol Oncol Clin North Am. 2018 Apr;32(2):xiii.

49.

A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.

Santini V, Allione B, Zini G, Gioia D, Lunghi M, Poloni A, Cilloni D, Sanna A, Masiera E, Ceccarelli M, Abdel-Wahab O, Terenzi A, Angelucci E, Finelli C, Onida F, Pelizzari A, Ferrero D, Saglio G, Figueroa M, Levis A.

Leukemia. 2018 Feb;32(2):413-418. doi: 10.1038/leu.2017.186. Epub 2017 Jun 13.

50.

Diagnosis and classification of hematologic malignancies on the basis of genetics.

Taylor J, Xiao W, Abdel-Wahab O.

Blood. 2017 Jul 27;130(4):410-423. doi: 10.1182/blood-2017-02-734541. Epub 2017 Jun 9. Review.

Supplemental Content

Loading ...
Support Center